Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
about
Resolution of inflammation: an integrated viewCyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosisGenetics of rheumatoid arthritis contributes to biology and drug discoveryInhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.CDK-mediated regulation of cell functions via c-Jun phosphorylation and AP-1 activation.Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokinesCyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review).Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas.Survivin is an essential mediator of arthritis interacting with urokinase signalling.DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.The Indispensable Role of Cyclin-Dependent Kinase 1 in Skeletal Development.The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages.Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.Effects of flavonoids and other polyphenols on inflammation.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Targeting neutrophil apoptosis for enhancing the resolution of inflammation.From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis.The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping.A novel mTOR inhibitor is efficacious in a murine model of colitis.Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.The binding of flavopiridol to blood serum albumin.Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis.Origins of fibroblasts in rheumatoid synovial tissues: Implications from organ fibrotic models.Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1β on rheumatoid arthritis fibroblast-like synoviocytes.Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.Selective inhibition of CDK7 ameliorates experimental arthritis in mice.Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
P2860
Q26852569-D2261E64-783D-415C-A24D-EF39693EB24BQ28732702-AE261818-EA75-4023-A1F7-423E70A417FAQ29417000-D9203C97-F7B2-49E2-8603-B230F89C4458Q30313935-4A5F7DFA-E612-497B-ABA9-A3FEEE8523C7Q30367060-EC18D7B0-2773-47FA-B825-83A1EF05F093Q33894814-0A2213A9-7D12-4E45-AB14-DFF595016563Q34022536-C00BC63A-295F-47D3-AC21-6EC91C0E735DQ34265421-A03CE483-A1AF-427E-9BB7-DB84B33F99DFQ35206166-AD62D634-D4B7-4979-9720-A19EA376763BQ35893385-409C89AC-59DE-4A1C-87EF-9ED71C84CC8EQ36010298-9DFE3728-A030-407C-AB35-B6792444747FQ36738991-6ABB2C68-794F-4AC0-8AEA-748C74D1DFF8Q36751676-A5AE1695-73C5-44C4-A27F-D83474A2B1B6Q37324160-80CDDB8C-BFDA-4876-92AF-741CC579A67DQ37602210-8111CB63-1149-4065-90EE-51CBB68D8049Q37856995-2F43B70A-45F3-4B52-8CC6-C0075000011CQ38008733-0BFB646D-0AC8-40A9-A72D-C8007B76E0DFQ38202818-95A43892-30A7-4DFC-A07B-FA26EB002CF0Q38233759-8BC55C03-F516-40ED-AACA-19CB28595BC6Q39343367-707E3DD3-641E-4F7E-8900-F653492C3030Q39928484-C14409D6-B877-446D-B51C-CE21F2953742Q42792282-DB86FFBC-D88E-415B-8256-0E8E99DFE31CQ42840918-312EC8E7-9244-4450-AB81-8819BDB7F416Q43473208-A5AB8B4D-C9E0-41D8-8C48-37E41ACAB398Q45990897-675337E1-8C3E-42FA-83DC-C1F4123E380CQ50079696-3B36EF2B-8135-4002-A553-F3DC25BB03FDQ51733013-0F200CFE-BF04-4E49-82FD-0F66DEA15809Q54320603-09947468-E75E-433D-A232-9EC2732F0B20Q54327713-0A7BF3D3-87A2-4C4E-87EC-28CC902A9328Q54536252-D49F7EAC-CEF4-45B8-A7F4-18C10D465ED4
P2860
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Successful treatment of animal ...... n-dependent kinase inhibitors.
@ast
Successful treatment of animal ...... n-dependent kinase inhibitors.
@en
Successful treatment of animal ...... n-dependent kinase inhibitors.
@nl
type
label
Successful treatment of animal ...... n-dependent kinase inhibitors.
@ast
Successful treatment of animal ...... n-dependent kinase inhibitors.
@en
Successful treatment of animal ...... n-dependent kinase inhibitors.
@nl
prefLabel
Successful treatment of animal ...... n-dependent kinase inhibitors.
@ast
Successful treatment of animal ...... n-dependent kinase inhibitors.
@en
Successful treatment of animal ...... n-dependent kinase inhibitors.
@nl
P2093
P1476
Successful treatment of animal ...... n-dependent kinase inhibitors.
@en
P2093
Chiyoko Sekine
Hiroshi Hirai
Hitoshi Kohsaka
Mitsuaki Yoshida
Nobuyuki Miyasaka
Sachiko Miyake
Takahiko Sugihara
P304
P356
10.4049/JIMMUNOL.180.3.1954
P407
P577
2008-02-01T00:00:00Z